(BIO101-COVA) Adaptive design phase 2 to 3, randomized, double-blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterioration in hospitalized patients with COVID-19 pneumonia (severe stage)

Have any questions? 706-721-6582 or cts@augusta.edu

Study Enrollment

Your details will not be published or shared.

Clinical Trial

(BIO101-COVA) Adaptive design phase 2 to 3, randomized, double-blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterioration in hospitalized patients with COVID-19 pneumonia (severe stage)

This study is for adults ages 18 and older who have a severe COVID-19 infection. The purpose is to see if a drug, Leronlimab (PRO 140), is a safe and effective treatment.

Eligibility Criteria

To be eligible, subjects must * be 18 of age or older * have a confirmed diagnosis of SARS-CoV-2 * be hospitalized * be free of other serious or underlying health conditions or recent history of health events

Contact Information

Shaheen Islam, MD

706 721-2566

sislam@augusta.edu

RESEARCH. INNOVATION. DISCOVERY.

Study Enrollment

Clinical Trial

(BIO101-COVA) Adaptive design phase 2 to 3, randomized, double-blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterioration in hospitalized patients with COVID-19 pneumonia (severe stage)

Eligibility Criteria

Contact Information

Augusta University

Research

AU Health

Stay Informed